Wielosz Ewa, Dryglewska Magdalena, Majdan Maria
Chair and Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Lublin, Poland.
Postepy Dermatol Alergol. 2020 Dec;37(6):909-914. doi: 10.5114/ada.2020.102107. Epub 2021 Jan 6.
Anti-RNA polymerase III (a-RNA Pol III) antibodies are marker antibodies in patients with systemic sclerosis (SSc).
To assess the prevalence of a-RNA Pol III in patients with SSc and to identify the differences in the disease picture in SSc patients with and without a-RNA Pol III antibodies.
The study was performed in 126 SSc patients. The subtype of SSc, incidence of internal organ involvement, malignancy, death and serological profiles were determined in the entire group. The study groups were studied according to the presence of antibodies by applying the commercial test - EUROLINE SSc Profile. Due to the presence of a-RNA Pol III, patients were divided into two groups: the a-RNA Pol III (+) SSc group of 19 patients and the a-RNA Pol III (-) SSc group of 107 patients.
A-RNA Pol III were present in 19/126 patients with SSc (15%), 13/19 (68.4%) patients had no other SSc marker antibodies. A-RNA Pol III were more common in patients with diffuse cutaneous SSc ( = 0.049). We showed a significant positive association between a-RNA Pol III and occurrence of malignancy ( = 0.007), scleroderma renal crisis ( = 0.001) and decreased DLCO ( = 0.007).
Anti-a-RNA Pol III antibodies are common in patients with SSc, particularly with a diffuse subtype. In more than 50% of patients with a-RNA Pol III antibodies, they may be present as the sole marker of antibodies. In SSc, a-RNA Pol III antibodies are frequently associated with malignancy occurrence, kidney and lung involvement.
抗RNA聚合酶III（a-RNA Pol III）抗体是系统性硬化症（SSc）患者的标志性抗体。
评估SSc患者中a-RNA Pol III的患病率，并确定有和没有a-RNA Pol III抗体的SSc患者在疾病表现上的差异。
对126例SSc患者进行了研究。确定了整个组中SSc的亚型、内脏器官受累的发生率、恶性肿瘤、死亡情况和血清学特征。通过应用商业检测-EUROLINE SSc Profile，根据抗体的存在情况对研究组进行了研究。由于存在a-RNA Pol III，患者被分为两组：19例a-RNA Pol III（+）SSc组和107例a-RNA Pol III（-）SSc组。
126例SSc患者中有19例（15%）存在a-RNA Pol III，19例患者中有13例（68.4%）没有其他SSc标志物抗体。a-RNA Pol III在弥漫性皮肤型SSc患者中更为常见（P = 0.049）。我们发现a-RNA Pol III与恶性肿瘤的发生（P = 0.007）、硬皮病肾危象（P = 0.001）和DLCO降低（P = 0.007）之间存在显著的正相关。
抗a-RNA Pol III抗体在SSc患者中很常见，尤其是弥漫性亚型。在超过50%的a-RNA Pol III抗体患者中，它们可能是唯一存在的抗体标志物。在SSc中，a-RNA Pol III抗体经常与恶性肿瘤的发生、肾脏和肺部受累相关。
